A roadmap for enterotoxigenic

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

1. A Double-Blind, Randomized Intervention Study on the Effect of a Whey Protein Concentrate onNutrients · 2022
   Trial
2. Characterization of the pathophysiological determinants of diarrheagenic Escherichia coli infection using a challenge model in healthy adults.Scientific reports · 2021
   Trial
3. Characterization of Glycosylation-Specific Systemic and Mucosal IgA Antibody Responses toFrontiers in immunology · 2021
   Trial
4. A 25-year landscape of Escherichia coli vaccine development: systematic review of human clinical studies.NPJ vaccines · 2026
   Article
5. Vaccine and Treatment Evaluation Units: A Historical Perspective.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
   Article
6. Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
   Article
7. Epidemiological and Clinical Features of EnterotoxigenicOpen forum infectious diseases · 2025
   Article
8. Role of cellular effectors in the induction and maintenance of IgA responses leading to protective immunity against enteric bacterial pathogens.Frontiers in immunology · 2024
   Review
9. The Controlled Human Infection Model for Enterotoxigenic Escherichia coli.Current topics in microbiology and immunology · 2024
   Review
10. The role of the minor colonization factor CS14 in adherence to intestinal cell models by geographically diverse ETEC isolates.mSphere · 2023
    Article
11. Strong Association between Diarrhea and Concentration of EnterotoxigenicPathogens (Basel, Switzerland) · 2023
    Article
12. Low doses of diarrhoeagenic E. coli induce enhanced monocyte and mDC responses and prevent development of symptoms after homologous rechallenge.PloS one · 2023
    Article
13. Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022
    Review
14. The role of CFA/I in adherence and toxin delivery by ETEC expressing multiple colonization factors in the human enteroid model.PLoS neglected tropical diseases · 2022
    Article
15. A multi-epitope fusion antigen candidate vaccine for Enterotoxigenic Escherichia coli is protective against strain B7A colonization in a rabbit model.PLoS neglected tropical diseases · 2022
    Article
16. Protection From Natural Immunity Against Enteric Infections and Etiology-Specific Diarrhea in a Longitudinal Birth Cohort.The Journal of infectious diseases · 2020
    Article
17. Human Mucosal IgA Immune Responses against EnterotoxigenicPathogens (Basel, Switzerland) · 2020
    Review
18. A tale of two bacterial enteropathogens and one multivalent vaccine.Cellular microbiology · 2019
    Review
19. Vaccines for enteric diseases.Human vaccines & immunotherapeutics · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract

Indexed as